Navigation Links
Avastin under trial to test efficacy for pancreatic tumours!

Northwestern Memorial Hospital along with Northwestern University Feinberg School of Medicine is conducting a Phase II clinical trial to determine if avastin is effective in pancreatic tumours.//

The drug also known as bevacizumab is an anti-angiogenesis drug that is designed to inhibit the growth of blood vessels in tumours.

The test is being done to see that it in combination with abdominal radiation therapy and chemotherapy can reduce localized pancreatic tumours that have not metastasized or spread to other systems or organs in the body.

Northwestern Memorial is the sole clinical site where the research trial is being conducted.

"Our findings from the previous study suggest that the combination of chemotherapy and radiation is a safe and effective treatment method to reduce the local extent of pancreatic tumors," said Dr. Talamonti, MD, chief of the Division of Surgical Oncology at Northwestern Memorial Hospital, associate professor of surgery at Northwestern University Feinberg School of Medicine and co-investigator on the study

Another view was presented by William Small, Jr., MD, radiation oncologist, Northwestern Memorial Hospital, associate professor, Radiation Oncology, Northwestern University Feinberg School of Medicine and principal investigator for the trial, "The current study, which will be conducted over two years, will help us evaluate whether adding Avastin may also provide an effective combination to reduce the tumour and increase survival rates. Avastin is designed to inhibit Vascular Endothelial Growth Factor (VEGF), a protein that plays an important role in tumour angiogenesis or blood vessel formation, and maintenance of existing tumour vessels. By inhibiting VEGF, Avastin is thought to interfere with the blood supply to tumours, a process that is critical to tumour growth and metastasis.”

As per statistics by the American Cancer Society, pancreatic cancer is the fourth leading cause of cancer death among adults in America. Approximately 1 out of 4 patients with pancreatic cancer will live at least one year after the cancer is found.

Therefore it is very important that clinical trials are conducted and new viable solutions are found for this problem.


'"/>




Related medicine news :

1. Avastin, anti-Cancer Drug leads to Blindness and Other Complications
2. Warning on Avastin Updated
3. FDA Approval for Lung Cancer Treatment -Avastin Along with Chemotherapy
4. Cancer Drug Avastin Fights Brain Tumors too
5. Antioxidants protect health tissue in people undergoing radiation therapy.
6. How do babies understand language?
7. Doctor samples come under the ambit of advertisement
8. Latest device for cardiac revival under test
9. Heart disease in women being under-treated
10. Safety of soy under suspicion
11. Education in women brings sounder sleep
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... , ... May 24, 2016 , ... Mental health watchdog ... the Church of Scientology and renowned professor of psychiatry Thomas Szasz, is continuing its ... “Psychiatry: An Industry of Death” exhibit in Atlanta, Georgia. The opening of the exhibit ...
(Date:5/24/2016)... ... , ... Boyd Industries, a leading supplier of dental chairs and cabinetry ... pediatric dentistry , at AAPD 2016, the annual conference and trade show of ... Delivery Unit keeps dental hand pieces and other anxiety-provoking pieces of the dental delivery ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... science and clinical practice of radiosurgery, is recognizing five medical residents and students ... and stereotactic body radiotherapy (SBRT). The awards will be presented at the 2016 ...
(Date:5/24/2016)... ... 24, 2016 , ... As reported by MassGeneral.org, on May 8 – 9, ... United States . The 64-year-old patient who received the transplant had undergone a partial ... only a natural appearance, but also urinary and sexual function for the patient who ...
(Date:5/24/2016)... ... May 24, 2016 , ... Harvard Health Publications, the consumer ... will deliver a new series of Q&A videos to clinicians and patients at ... expertise of Harvard Medical School faculty into brief videos that clinicians using vidscrip ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 24, 2016 ... , la première endoprothèse à double thérapie ... l,intervention portant sur les membres inférieurs et ... OrbusNeich, entreprise mondiale spécialisée dans la fourniture ... vie, a élargi son portefeuille pour inclure ...
(Date:5/23/2016)... 2016 Global Paclitaxel Market 2016 ... 12 companies and the Paclitaxel analysis in this study ... industry and its players. This is the ... details the current state of the industry while providing ... applications and industry chain structure. The Paclitaxel market analysis ...
(Date:5/23/2016)... , May 23, 2016 The World Health ... PrePex device to include adolescents aged 13 years, and ... can be offered for adult and adolescent males in the ... . PrePex was the first male circumcision device to ... MedTech,s CEO, Eddy Horowitz said: " The ...
Breaking Medicine Technology: